XML 44 R33.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACCOUNTS RECEIVABLE (Tables)
 3 Months Ended
Mar. 31, 2016
Receivables [Abstract]  
Schedule of Accounts, Notes, Loans and Financing Receivable
The composition of accounts receivable, net is as follows (in thousands):
 
March 31, 2016
 
December 31, 2015
Gross accounts receivable (1)
$
729,060

 
$
738,730

Less: Rebate reserve
(320,013
)
 
(265,229
)
Less: Chargeback reserve
(104,293
)
 
(102,630
)
Less: Distribution services reserve
(11,638
)
 
(12,576
)
Less: Discount reserve
(15,469
)
 
(18,657
)
Less: Uncollectible accounts reserve (2)
(63,199
)
 
(15,187
)
Accounts receivable, net
$
214,448

 
$
324,451


(1) Includes estimated $48.0 million and $40.6 million as of March 31, 2016 and December 31, 2015, respectively, receivable due from Turing for reimbursement of Daraprim® chargebacks and Medicaid rebate liabilities.
(2) As a result of the uncertainty of collection that has developed since the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, the Company recorded a reserve of $48.0 million as of March 31, 2016, which represents the full amount of the estimated receivable due from Turing as of that date. See "Note 4. Summary of Significant Accounting Policies - Concentration of Credit Risk" for additional information regarding the Turing receivable.
Allowance for Credit Losses on Financing Receivables
A roll-forward of the rebate and chargeback reserves activity for the three months ended March 31, 2016 and the year ended December 31, 2015 is as follows (in thousands):
Rebate reserve
March 31, 2016
 
December 31, 2015
Beginning balance
$
265,229

 
$
88,812

Acquired balances
—

 
75,447

Provision recorded during the period for Impax Generics rebates
185,476

 
571,642

Credits issued during the period for Impax Generics rebates
(130,692
)
 
(470,672
)
Ending balance
$
320,013

 
$
265,229

The payment mechanisms for rebates in the Impax Generics and Impax Specialty Pharma divisions are different, which impacts the location on the Company's balance sheet. Impax Specialty Pharma rebates are classified as Accrued Expenses on the Company's consolidated balance sheets.

Chargeback reserve
March 31, 2016
 
December 31, 2015
Beginning balance
$
102,630

 
$
43,125

Acquired balances
—

 
24,532

Provision recorded during the period
223,465

 
833,157

Credits issued during the period
(221,802
)
 
(798,184
)
Ending balance
$
104,293

 
$
102,630